Targeted 3 Tesla multiparametric Prostate MR-TRUS Fusion Biopsy is a method that detects cancer-suspected areas in the prostate using advanced technology devices and software, allowing biopsies to be performed on these areas with millimetric precision. This method enables cancer foci to be detected with higher accuracy, reducing the need for repeat biopsies.
The definitive diagnosis of prostate cancer is to demonstrate the presence of cancer by taking a sample from prostate tissue. This procedure is called a prostate biopsy. Today, the diagnostic effectiveness of the standard 10-12 core transrectal systematic biopsy accepted in prostate cancer diagnosis is limited. In series compared with autopsy series, prostate biopsy sensitivity has been reported as 53%. Due to this uncertainty, approximately one-third of cases undergo repeat biopsies within five years, and tumors are detected in 13-41% of these cases. To overcome these issues, biopsies with more extensive sampling have been recommended, which clinically increase the rate of insignificant tumor detection and consequently the risk of unnecessary treatment.
Recently, developments in the field of Multiparametric Magnetic Resonance Imaging (mp-MRI) conducted with 3 Tesla MRI have shown that the accuracy of prostate cancer diagnosis and classification can be increased. In advanced centers, biopsy methods targeting lesions detected in mp-MRI have come to the forefront. These methods allow the diagnosis of low-grade tumors by using pre-detection of suspicious areas with high-resolution 3 Tesla Multiparametric MRI performed before the biopsy, and then transferring these areas to a special ultrasound device (fusion biopsy device) to obtain targeted samples from these suspicious areas. In other words, prostate biopsy (fusion biopsy) is the most up-to-date prostate cancer diagnosis method that minimizes the chance of missing prostate cancer. It is applied in a few centers in our country.